X4P-001 ( DrugBank: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	11

65. Primary immunodeficiency

Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

diseases per page:

Showing 1 to 10 of 11 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001153-10-GB (EUCTR)	21/12/2020	29/06/2020	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor	X4 Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	28	Phase 3	United States;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Can ...
2	EUCTR2019-001153-10-DE (EUCTR)	20/10/2020	26/03/2020	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor	X4 Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 3	Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Netherlands;G ...
3	EUCTR2019-001153-10-AT (EUCTR)	16/10/2020	24/03/2020	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor	X4 Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	28	Phase 3	United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Can ...
4	EUCTR2019-001153-10-NL (EUCTR)	09/09/2020	06/04/2020	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor	X4 Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	28	Phase 3	United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Can ...
5	EUCTR2019-001153-10-PL (EUCTR)	27/04/2020	09/03/2020	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor	X4 Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 3	United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Can ...
6	EUCTR2019-001153-10-ES (EUCTR)	02/03/2020	02/12/2019	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor	X4 Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	28	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Portugal;United States;Spain;Turkey;Austria;Israel;Italy;United Kingdom;France;Hungary;European Unio ...
7	EUCTR2019-001153-10-IT (EUCTR)	18/02/2020	17/06/2021	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10020986;Term: Hypogammaglobulinem ...	Product Name: Mavorixafor Product Code: [X4P-001] INN or Proposed INN: Mavorixafor	X4 PHARMACEUTICALS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	28	Phase 3	United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Can ...
8	EUCTR2019-001153-10-FR (EUCTR)	05/02/2020	16/10/2019	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10010512;Term: Congenital immunode ...	Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor	X4 Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	28	Phase 3	United States;Portugal;Spain;Turkey;Austria;Israel;United Kingdom;Italy;France;Hungary;European Unio ...
9	EUCTR2019-001153-10-HU (EUCTR)	08/01/2020	08/11/2019	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor	X4 Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 3	United States;Portugal;Spain;Turkey;Austria;Israel;United Kingdom;Italy;France;Hungary;European Unio ...
10	EUCTR2019-001153-10-DK (EUCTR)	16/12/2019	21/10/2019	A treatment study in patients with WHIM Syndrome.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patient ...	WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor	X4 Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	28	Phase 3	United States;Spain;Austria;Israel;Russian Federation;Italy;United Kingdom;France;Hungary;Poland;Den ...

First Previous1 2Next Last